Drugs / Travelan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05933525 Comparator | May 2023 → Jul 2024 | diarrheal disease, intestinal infectious disease | Immuron Ltd. | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-14 | Immuron Ltd. | Immuron Announces Travelan Clinical Trial Update immuron.com.au ↗ |
| 2024-03-06 | Immuron Ltd. | Travelan to progress to Phase 3 Clinical Trials in the US immuron.com.au ↗ |
| 2023-10-18 | Immuron Ltd. | Travelan Clinical Study Cohort 2 commences immuron.com.au ↗ |
| 2023-07-24 | Immuron Ltd. | Immuron enrols patients in Travelan clinical study immuron.com.au ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Travelan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05933525 ↗ |
| Route | Oral | “Travelan tablets (1200mg) administered orally once daily for 7 days” NCT05933525 ↗ |